Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Triptorelin

Decapeptyl · GnRH Long-Acting Agonist

Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.

Triptorelin is an FDA-approved GnRH agonist with strong multi-RCT evidence for its labeled uses. Trelstar (triptorelin pamoate) is approved for advanced prostate cancer on the strength of randomized active-controlled trials versus other GnRH agonists showing castrate-level testosterone suppression, and Triptodur (6-month depot) is FDA-approved for central precocious puberty in children 2 and older with a phase 3 trial reporting prepubertal LH suppression maintained at 12 months in about 98 percent of patients. Abroad, formulations (Decapeptyl) are widely approved for endometriosis, uterine fibroids, and IVF/assisted-reproduction protocols, so grade 5 stands for these approved oncology and endocrine indications; the gray-market off-label bodybuilding use as a one-shot post-cycle HPTA/testosterone reset rests on case reports and forum reports and is unapproved.

FDA
FDA Approved: Trelstar (triptorelin pamoate) for advanced prostate cancer; Triptodur (triptorelin depot) for central precocious puberty in children 2+
WADA
Prohibited in males only (S2); permitted in females

Reference only. Not medical advice.

What can go wrong

Profound hypogonadism, initial testosterone flare that can transiently worsen prostate-cancer symptoms, bone-density loss with prolonged use; off-label HPTA-reset use is unapproved and dose-sensitive.

Talk to a clinician before taking this, particularly if you have any history of cancer. The Atlas can tell you what has been studied about Triptorelin. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A long-acting GnRH agonist, FDA-approved for prostate cancer via androgen deprivation. Used off-label in some hormone protocols.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Prostate cancer / androgen deprivation (approved)
Advanced prostate cancer (Trelstar)
FDA-approved in 2000 for the palliative treatment of advanced prostate cancer by lowering testosterone to castration levels, as effective as surgical castration and a first-line hormone therapy.
Endometriosis and uterine fibroids
Approved to lower estrogen and treat endometriosis and uterine fibroids, used short-term, around six months, to limit bone loss.
Central precocious puberty
Approved to suppress premature puberty in children, a genuine pediatric use under specialist care.

How it works

Triptorelin is a GnRH agonist: by continuously stimulating the pituitary it ultimately shuts down the release of the hormones that drive testosterone and estrogen production. That deep hormone suppression is useful in hormone-dependent conditions, most notably advanced prostate cancer, and in several gynecologic and pediatric settings.

Triptorelin is a synthetic decapeptide analog of GnRH (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2), the natural hormone with a single change, a D-tryptophan at position six, that gives it roughly a hundred times the receptor affinity and a much longer duration. That makes it a GnRH superagonist. Sold as Trelstar, Decapeptyl and Diphereline, it is given as long-acting depot injections lasting one, three or six months.

Type
GnRH agonist decapeptide
Action
Flare, then suppression
Result
Medical castration
Form
Long-acting depot
Approved
Prostate cancer (2000)
WADA
Prohibited (males)

An Agonist That Shuts The Axis Down

Triptorelin is the clearest illustration of why pulsatility governs the reproductive axis, and it pairs instructively with gonadorelin. Both are GnRH analogs hitting the same pituitary receptor, but they exploit it in opposite ways: gonadorelin is pulsed to stimulate the axis, while triptorelin, given continuously, first stimulates (a transient testosterone flare) and then, by overstimulating the receptor without pause, desensitizes it and shuts the axis down to castration levels. That suppression is the therapeutic goal, and it is genuinely FDA-approved and important: lowering testosterone to treat prostate cancer, lowering estrogen to treat endometriosis, and halting premature puberty in children. The honest caveat is a gray-market one: bodybuilders use triptorelin off-label as a single-dose restart after steroid cycles, trying to harness the initial flare to reboot natural testosterone, but that protocol is thinly evidenced, can backfire into the very suppression they are trying to avoid, and is banned in sport.

Safety in detail

The gray-market off-label use as a single-injection post-cycle testosterone/fertility reset is unapproved and is supported only by a case report and bodybuilding-forum reports; high doses can paradoxically suppress the HPTA rather than restart it. WADA prohibits GnRH agonists in male athletes.

  • An initial testosterone or estrogen surge (flare) can transiently worsen symptoms before suppression takes hold.
  • Long-term suppression causes hot flashes, bone density loss and other low-hormone effects, managed with monitoring.
  • It is a specialist hormonal therapy with a well-characterized profile.

Children and teenagers

Triptorelin has a genuine, important pediatric use: suppressing central precocious puberty under pediatric endocrinology, and, per clinical practice, as a puberty blocker in gender-affirming care for adolescents under specialist care. These are legitimate, supervised medical uses, a real exception in this library. They are entirely separate from off-label hormone or bodybuilding use, which has no pediatric application. Any pediatric use belongs strictly with specialists.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Triptorelin is a major approved pharmaceutical, sold as Trelstar, Decapeptyl and Diphereline and now generically, generating substantial revenue in oncology and reproductive medicine despite generic availability, as GnRH analogs remain expensive. A small, separate off-label market exists in bodybuilding, where it is diverted or gray-market-sourced for steroid-cycle recovery. The overwhelming majority of its use, and its money, is legitimate approved medicine.

How we got here

Triptorelin is a synthetic decapeptide GnRH (LHRH) agonist developed by Ipsen and marketed across Europe as Decapeptyl, along with Diphereline and Gonapeptyl. In the United States it is sold as Trelstar and as the six-month depot Triptodur, primarily for advanced prostate cancer and central precocious puberty.

After GnRH was discovered in 1971, agonist analogs were developed in the 1980s, their names ending in -relin, and triptorelin, with its D-tryptophan substitution, became one of the major superagonists. It earned approvals across prostate cancer, endometriosis, fibroids and precocious puberty, with US prostate-cancer approval in 2000, and long-acting depots progressed from monthly to six-month dosing. Generics followed, and alongside its established medical use it acquired off-label roles in gender-affirming care and, in fitness circles, as a steroid-cycle restart agent.

  1. 1971GnRH is discovered, opening the door to analogs.
  2. 1980sGnRH agonists, including triptorelin, are developed for medical use.
  3. 2000The FDA approves triptorelin for advanced prostate cancer.
  4. 2000s-2010sLong-acting depots extend to three- and six-month dosing; generics arrive.
  5. 2010s-2020sOff-label gender-affirming and bodybuilding-restart uses spread alongside its core medical role.

The numbers behind the grade

Type
GnRH agonist (decapeptide)
Brand
Trelstar / Decapeptyl
Approved
Yes
Main use
Prostate cancer
Also
Endometriosis, puberty
Class
Hormone suppression

The people taking it

A well-established GnRH agonist, best known for prostate-cancer hormone therapy and for managing precocious puberty, in the same family as the better-known leuprolide.

Triptorelin’s users are predominantly men with prostate cancer, the main approved population, along with women with endometriosis or fibroids, children with precocious puberty under specialists, and patients in breast-cancer, fertility and gender-affirming care. A small, separate off-label group is bodybuilders using it for steroid-cycle recovery. The clinical population vastly outnumbers the off-label one.

Used worldwide to suppress sex hormones in prostate cancer, endometriosis, fibroids, precocious puberty and fertility care. A genuine approved hormonal therapy under specialist management.

Set against the alternatives

The most illuminating comparison is to gonadorelin: the same GnRH receptor, exploited in opposite directions. Gonadorelin is pulsed to stimulate the axis and preserve fertility, while triptorelin is given continuously to suppress it, and together they show that pulsatility is everything. Against other GnRH agonists like leuprolide, goserelin and nafarelin, triptorelin is one of the major, near-equivalent members of a well-established class. Against the newer GnRH antagonists such as degarelix, which block the receptor directly and suppress hormones without the initial flare, triptorelin’s flare is a relative drawback in prostate cancer. And against its own off-label bodybuilding restart use, the contrast is stark: the approved suppression use is rigorously evidenced, while the flare-based restart is not. Its strength is a clear, proven therapeutic role; its main nuance is the flare it must work around.

What we do not know

  • How best to mitigate the bone and metabolic effects of long-term hormone suppression.
  • How it compares with GnRH antagonists for specific uses.

What could change

Antagonist competitionFlare-free GnRH antagonists challenge agonists in prostate cancer.Gender-affirming careIts puberty-suppression use is clinically important and publicly debated.New formulationsLonger-acting and easier-to-administer depots continue to develop.Off-label fitness useBodybuilding restart use persists on thin evidence.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Available only by prescription as an approved specialist drug, typically given as a depot injection by a clinician. It is a regulated medical therapy, not a gray-market peptide.

Triptorelin is an established prescription depot drug, still relatively expensive even with generics available, as is typical for GnRH analogs. The off-label gray-market supply used in bodybuilding is cheaper and unregulated.

Manufactured as an approved pharmaceutical under full regulation; a controlled, traceable supply.

Regulated pharmaceuticalTriptorelin is an approved depot drug supplied through oncology and specialist channels, branded and generic, with full quality assurance.Specialist administrationIt is given as a long-acting depot injection under medical care.Off-label diversionA small gray-market or diverted supply feeds off-label bodybuilding use.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Triptorelin.

Nothing outstanding on this one.

Sources

The studies that matter

  • Prostate cancer androgen deprivationestablished

    Long-standing use to suppress testosterone in advanced prostate cancer, slowing hormone-driven tumor growth.

  • Endometriosis, fibroids and precocious pubertyestablished

    Approved and used to suppress sex hormones in endometriosis and fibroids, and to halt premature puberty in children, with careful specialist oversight.